Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spectrum 5: DE-117 in Glaucoma
NCT03697811Phase 3Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Sep 2018
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of omidenepag isopropyl in primary open-angle glaucoma (POAG) and ocular hypertension, sponsored by Santen Pharmaceutical. Primary endpoint: Change From Baseline in Mean Diurnal Intraocular Pressure (IOP) at Month 3. Started Sep 2018; status: completed.
02
Drugs
omidenepag isopropyl
03
Conditions
primary open-angle glaucoma (POAG)ocular hypertension
Beyond the preview
Go deeper on NCT03697811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03697811.